- Generic Name:
- Drug Type:
- Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
- How the Drug is Given:
Injection, for subcutaneous use
Indications and Usage
Elranatamab-bcmm is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Side effects needing medical attention
Most common adverse reactions are cytokine release syndrome (CRS), fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and fever. The most common laboratory abnormalities are decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets.